Among the current drugs that promote uric acid excretion for the treatment of hyperuricemia, the URAT1 inhibitor SHR4640 has achieved significant research and development results: Verified by subHUA (24-hour subacute hyperuricemia) and Ch-HUA (21-day chronic hyperuricemia) mouse models, its 50 mg/kg dose can effectively reduce uric acid in both models (serum uric acid decreased by 42% 3 days after Ch-HUA administration), and long-term administration causes no renal damage. The gene discussed is SLC22A12; the disease is hyperuricemia.